Evidence map›Paper›PMID 41973218›Full record

ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026

[Antibiotics and phages: effects of combined therapy on susceptibility and resistance of bacterial pathogens].

Peter Heisig, Anke Heisig

Abstract readEnglish AbstractReview
In one paragraph

Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Peter HeisigInstitut für Biochemie und Molekularbiologie, Universität Hamburg, Bundesstraße 45, 20146, Hamburg, Deutschland.
Anke HeisigInstitut für Biochemie und Molekularbiologie, Universität Hamburg, Bundesstraße 45, 20146, Hamburg, Deutschland. anke.heisig@uni-hamburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing use of antibiotics both in human therapy and for non-therapeutic applications with simultaneous reduction in antibiotic drug development have led to a world-wide rise in antibiotic resistance. Before the age of antibiotics, bacteriophages (phages) were already used initially in France and Georgia and later in the USA and Russia. Today, phages are increasingly being used to treat infections caused by antibiotic-resistant bacteria either alone or in combination with antibiotics.Combining phages with antibiotics reduces the likelihood of simultaneous resistance development against both agents. In contrast to chemically defined antibiotics, phages have the ability to adapt to resistant host cells through genetic mechanisms. However, bacterial mutants that confer antibiotic resistance could simultaneously limit the effectiveness of phages. To avoid such effects, detailed knowledge of the mechanism of action and resistance of the antibiotic as well as the replication strategy of the phage is required. For the individual steps in the replication cycle of the lytic phages, the possible effects on resistance to the corresponding phages are analyzed for host cell factors associated with antibiotic resistance. Based on selected combinations, it becomes evident that resistance to one component is often accompanied by increased sensitivity to the other, which significantly reduces the likelihood of simultaneous resistance to both. Particularly efficient appear to be synergistic combinations, such as those consisting of an antibiotic and endolysin, a bactericidal phage enzyme.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsBacteriophagesDrug Resistance, BacterialPhage TherapyCombined Modality TherapyHumansTreatment OutcomeAnti-Bacterial AgentsAdaptionAntibiotic resistanceBacteriophageCombination therapyEndolysin

Identifiers

PMID41973218
PMCPMC13132894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.